Linked Life Data

18347538

Source:http://linkedlifedata.com/resource/pubmed/id/18347538

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
2008-3-18
pubmed:abstractText
Transplantation-induced systemic endothelial dysfunction causes severe cardiovascular morbidity and mortality after transplantation. Interventions that improve systemic endothelial function after transplantation and furthermore reduce intragraft vascular dysfunction might improve graft and patient survival. Treatment with the PPARgamma agonist rosiglitazone is an intervention that potentially fulfills these criteria. In this study, we determined the effect of rosiglitazone treatment on transplantation-induced endothelial dysfunction and vasomotor activity in an experimental model for chronic transplant dysfunction in rats.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Feb
pubmed:issn
0041-1337
pubmed:author
pubmed:issnType
Print
pubmed:day
27
pubmed:volume
85
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
582-8
pubmed:meshHeading
pubmed:year
2008
pubmed:articleTitle
Dichotomous effects of rosiglitazone in transplantation-induced systemic vasodilator dysfunction in rats.
pubmed:affiliation
Department of Cell Biology, Section Immunology, University Medical Center Groningen, University of Groningen, 9700 RB Groningen, the Netherlands.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't